Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The OTCBB Garbage Dump -- Ignore unavailable to you. Want to Upgrade?

To: Tom Allinder who wrote (2744)	10/12/1999 12:58:00 PM
From: Mr.Manners	Read Replies (1) \| Respond to of 2942

MEDJ Tuesday October 12, 11:30 am Eastern Time Company Press Release SOURCE: Medi-Ject Corp. Medi-Ject Corporation Announces Asian Device Approvals and First Product Shipment to SciGen Medi-Ject Expands its Asian Presence Beyond Japan and Begins Shipments Of Needle-Free Injectors for Human Growth Hormone to Additional Markets In Southeast Asia MINNEAPOLIS, Oct. 12 /PRNewswire/ -- Medi-Ject Corporation (Nasdaq: MEDJ - news) today announced that one of its pharmaceutical partners, SciGen Pte Ltd of Singapore, has received government approvals to market a Medi-Ject needle-free injector, the SciTojet, for human growth hormone injections in several southeast Asian markets, including Hong Kong, The Philippines, Singapore and Malaysia. As a result of these approvals, Medi-Ject Corporation announced the first shipment of SciTojet injectors to SciGen Pte Ltd. ''Asia is a large and attractive market opportunity for our growth hormone needle-free injectors,'' said Dr. Franklin Pass, Chairman and CEO of Medi-Ject. ''We have already had good success in Japan, where our growth hormone injector has been very well accepted by children and their parents. In Asia, we hope to duplicate the market penetration we have begun to achieve in Europe. The basis for our success in these markets is that our growth hormone injector fills an important market need: independent studies show that the daily administration of growth hormone without a needle is preferred over needle alternatives, especially among children.'' Any statements released by Medi-Ject that are forward looking, including statements relating to future product development, product sales, development and licensing agreements, and research activities, are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward looking statements involve risks and uncertainties which may affect the Company's business and prospects, including changes in economic and market conditions, healthcare legislation, progress in Medi-Ject's alliances with pharmaceutical companies, the development of competing drug delivery systems, management of growth and other factors discussed in the Company's filings with the Securities and Exchange Commission. Medi-Ject Corporation is the world's leading developer and marketer of needle-free drug delivery systems. The Company manufactures hand-held injectors that deposit pharmaceuticals, including insulin and growth hormone, under the skin without a needle. Presently, these needle-free injection systems are distributed in over twenty countries. Headquartered in Minneapolis, the Company's common stock is traded on the Nasdaq Small Cap Market under the symbol MEDJ. Company information can be found on the Internet under Medi-Ject's site on the World Wide Web at mediject.com . For more information on Medi-Ject Corporation via facsimile at no additional cost, simply dial 1-800-PRO-INFO and enter company's ticker symbol MEDJ. SOURCE: Medi-Ject Corp. More Quotes and News: Medi-Ject Corp (NasdaqSC:MEDJ - news) Related News Categories: medical/pharmaceutical

To: Tom Allinder who wrote (2744)	10/13/1999 12:12:00 AM
From: carromill	Read Replies (1) \| Respond to of 2942

Just to advise you ...Shorters and non-reporting did not run this stock down..It was the constant DILUTION of authorized to public float (which from my tracking, over last 6 mos) s/b in the 60-80 mil range> Buy-out would be big 10 to 1 r/s due to heavy WEB Development expenses and payng for Internet "Spread" without useing (non)-existing cash, PLUS not having enough real revenues to take a chance of "reporting" that fact! I too believe a buy-out will be the only thing in the end (of the year) that will allow SIrlin and Newell to walk away saving face!!! I have fond appreciation for this (MAKO)..its wonderful (first impressions,of things to come!) run-up in April is what gave me my greatest profits .. It just is getting heavily weighted down With " Lets Try This, No. Lets Try This, or Maybe this...put a name on it and run it up the flag pole and see who pays..Hey, we could do this forever! until mandated Filing...But still too far off and we still have 20mil more authorized to get into//// not BASHING! just offering for DD balance